Zobrazeno 1 - 10
of 30
pro vyhledávání: '"High-risk Bladder Cancer"'
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundDue to the poor prognosis, the treatment of high-risk bladder cancer (HRBC) remains controversial. This meta-analysis aims to access the efficacy of intra-arterial chemotherapy (IAC) combined with intravesical chemotherapy (IC) versus IC al
Externí odkaz:
https://doaj.org/article/1bbef8d4f21d4c8f8ce94868a7e93ce7
Autor:
Dafina Ilijazi, Walter Pulverer, Iris E. Ertl, Ursula Lemberger, Shoji Kimura, Mohammad Abufaraj, David D’Andrea, Benjamin Pradere, Andreas Bruchbacher, Anna Graf, Francesco Soria, Martin Susani, Andrea Haitel, Luca Molinaro, Armin Pycha, Evi Comploj, Stephan Pabinger, Andreas Weinhäusel, Gerda Egger, Shahrokh F. Shariat, Melanie R. Hassler
Publikováno v:
Cells, Vol 9, Iss 8, p 1839 (2020)
Background: Bacillus Calmette-Guérin (BCG) immunotherapy, the standard adjuvant intravesical therapy for some intermediate and most high-risk non-muscle invasive bladder cancers (NMIBCs), suffers from a heterogenous response rate. Molecular markers
Externí odkaz:
https://doaj.org/article/837a12d883f24e87bf5c66e235db5396
Autor:
George E. Koch, Sam S. Chang
Publikováno v:
Üroonkoloji Bülteni, Vol 19, Iss 4, Pp 167-174 (2020)
Non-muscle invasive bladder cancer is a heterogeneous disease with widely varying risks of recurrence and progression to muscle invasion. Risk stratification within current treatment guidelines are an attempt to address this heterogeneity. This heter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e58cb27d8aa839d6c32d5ec06042bbb9
https://doi.org/10.4274/uob.galenos.2020.1549
https://doi.org/10.4274/uob.galenos.2020.1549
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology
Frontiers in Oncology
BackgroundDue to the poor prognosis, the treatment of high-risk bladder cancer (HRBC) remains controversial. This meta-analysis aims to access the efficacy of intra-arterial chemotherapy (IAC) combined with intravesical chemotherapy (IC) versus IC al
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e88ac1c867238bd54b5ec1da924a24d3
https://www.frontiersin.org/articles/10.3389/fonc.2021.651657/full
https://www.frontiersin.org/articles/10.3389/fonc.2021.651657/full
Autor:
C Bettocchi, Luigi Cormio, Francesca Sanguedolce, Francesca Fortunato, Beppe Calò, Giuseppe Carrieri, Gian Maria Busetto, Ugo Falagario, Marco Chirico, Emanuel Carvalho-Diaz
Publikováno v:
World Journal of Urology
Purpose To determine the need for routine bladder biopsies (BBs) in assessing response to the induction cycle of intravesical bacillus Calmette–Guérin (BCG) for high-risk non-muscle-invasive bladder cancer (NMIBC). Methods Our prospectively mainta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42ba7bdd4364823066a3f7a0d4239852
https://pubmed.ncbi.nlm.nih.gov/34101020
https://pubmed.ncbi.nlm.nih.gov/34101020
Autor:
Gerda Egger, Andrea Haitel, Dafina Ilijazi, Luca Molinaro, Benjamin Pradere, Andreas Bruchbacher, Ursula Lemberger, Martin Susani, Francesco Soria, Shahrokh F. Shariat, Shoji Kimura, Walter Pulverer, Stephan Pabinger, Melanie R. Hassler, Mohammad Abufaraj, Andreas Weinhäusel, David D'Andrea, Evi Comploj, Anna Graf, Iris E Ertl, Armin Pycha
Publikováno v:
Cells
Volume 9
Issue 8
Cells, Vol 9, Iss 1839, p 1839 (2020)
Volume 9
Issue 8
Cells, Vol 9, Iss 1839, p 1839 (2020)
Background: Bacillus Calmette-Gué
rin (BCG) immunotherapy, the standard adjuvant intravesical therapy for some intermediate and most high-risk non-muscle invasive bladder cancers (NMIBCs), suffers from a heterogenous response rate. Molecul
rin (BCG) immunotherapy, the standard adjuvant intravesical therapy for some intermediate and most high-risk non-muscle invasive bladder cancers (NMIBCs), suffers from a heterogenous response rate. Molecul
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08b7e4dc277c7315a68dc085ffe43cea
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jeffrey J. Leow, Anna Orsola, Justine A. Barletta, J Morote, Joaquim Bellmunt, I. De Torres, Fernando Lozano, William Martin-Doyle, Lillian Werner, Stephanie A. Mullane, C.X. Raventós
Publikováno v:
British Journal of Cancer
Background: Management of high-grade T1 (HGT1) bladder cancer represents a major challenge. We studied a treatment strategy according to substaging by depth of lamina propria invasion. Methods: In this prospective observational cohort study, patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f7900a919fabb303c412f674a612efc
https://pubmed.ncbi.nlm.nih.gov/25535728
https://pubmed.ncbi.nlm.nih.gov/25535728
Publikováno v:
WORLD JOURNAL OF UROLOGY
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Despite standard treatment with transurethral resection (TUR) and adjuvant bacillus Calmette-Gu,rin (BCG), many high-risk bladder cancers (HRBCs) recur and some progress. Based on a review of the literature, we aimed to establish the optimal current
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::ef32bd8a62d176e6eaf15f31c1c4b1ed
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=10996
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=10996
